Kenneth Reay Code’s father had a stroke nearly a decade ago, leaving him significantly impaired. This limited mobility put his father in a risky position of needing long-term convalescent care where he would be exposed to the risks of secondary infection often faced in a care facility. Concerned about the legitimate risks to his father’s health, Code was determined to improve his father’s quality of life and extend his life expectancy by reducing the compounding risks of secondary infection. The result of this determination was BioLargo Technology, a blend of inorganic chemical compound and absorbent materials used as an effective instrument in preventing the transmission of life threatening infection.
The BioLargo Technology places basic, safe, and inorganic compounds into absorbent products found in healthcare environments, such as bed pads, blood pads, diapers, surgical drapes, transportation packages for protective liners, wound dressings, bandages, etc. The technology can also be also placed in liquid, tablet, powders, sprays, washes, and gas phase delivery systems.
When the BioLargo Technology is incorporated into these types of products, the results are potent, safe, and degradable germ killing products that mitigate the often fatal risks of infection.
Now a publicly traded company, BioLargo holds five issued U.S. patents and is on record with more than 20 additional patent applications at the U.S. Patent and Trademark Office relating to additional uses of the chemistry, the reactions and the applications of the BioLargo Technology. Utilizing this technology, BioLargo is developing products and services offered through several company subsidiaries subsidiaries.
BioLargo Water is focused on Advanced Oxidation Systems (AOS) such as the AOS Filter, a development-stage product designed to eliminate common toxic contaminants found in water in a more time efficient and less expensive manner than current technologies. BioLargo also owns a 50 percent interest in the Isan System, which was given the “Top 50 Water Company for the 21st Century” award by the Artemis Project. The subsidiary Odor-No-More Inc. offers products serving the pet, equine, and consumer markets, including the Nature’s Best Solution® and Deodorall® brands. The Clyra Medical Technologies, Inc. subsidiary focuses on advanced wound care management and is preparing to make U.S. FDA 510(k) applications in 2014.
For more information, visit www.biolargo.com
Let us hear your thoughts below: